Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
AEON Stock Summary
Top 10 Correlated ETFs
AEON
In the News
Atalaya Capital Management LP Acquires New Stake in AEON Biopharma Inc
Atalaya Capital Management LP (Trades, Portfolio), a New York-based investment firm, recently made a significant acquisition in AEON Biopharma Inc. This article will delve into the details of the transaction, provide an overview of both Atalaya Capital Management LP (Trades, Portfolio) and AEON Biopharma Inc, and analyze the potential impact of this acquisition on the firm's portfolio and the traded company's stock performance.
AEON Financial details
AEON Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 |
---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0.23 | 0.17 | 0 | 0 | |
Net income per share | 11.69 | -2.22 | -2.53 | 0 | |
Operating cash flow per share | -3.02 | -0.64 | -1.29 | 0 | |
Free cash flow per share | -3.14 | -0.64 | -1.3 | 0 | |
Cash per share | 7.55 | 1.36 | 0.23 | 0 | |
Book value per share | -4.54 | -14.08 | -10.68 | 0 | |
Tangible book value per share | -4.45 | -13.74 | -10.18 | 0 | |
Share holders equity per share | -4.54 | -14.08 | -10.68 | 0 | |
Interest debt per share | 2.53 | 4.88 | 3.95 | 0 | |
Market cap | 136.13M | 136.13M | 202.36M | 0 | |
Enterprise value | 159.75M | 188.12M | 284.13M | 121.79M | |
P/E ratio | 0.79 | -4.14 | -3.64 | 0 | |
Price to sales ratio | 40.55 | 54.06 | 0 | 0 | |
POCF ratio | -3.04 | -14.39 | -7.12 | 0 | |
PFCF ratio | -2.93 | -14.39 | -7.07 | 0 | |
P/B Ratio | -2.03 | -0.65 | -0.86 | 0 | |
PTB ratio | -2.03 | -0.65 | -0.86 | 0 | |
EV to sales | 47.59 | 74.71 | 0 | 0 | |
Enterprise value over EBITDA | -3.17 | -8.5 | -35.91 | -2.52 | |
EV to operating cash flow | -3.57 | -19.88 | -9.99 | -3.42 | |
EV to free cash flow | -3.44 | -19.88 | -9.93 | -3.39 | |
Earnings yield | 1.27 | -0.24 | -0.27 | 0 | |
Free cash flow yield | -0.34 | -0.07 | -0.14 | 0 | |
Debt to equity | -0.45 | -0.35 | -0.37 | -0.46 | |
Debt to assets | 0.26 | 3.4 | 13.5 | 12.2 | |
Net debt to EBITDA | -0.47 | -2.35 | -10.33 | -2.52 | |
Current ratio | 6.41 | 4.85 | 0.25 | 0.12 | |
Interest coverage | -7.22 | -1.09K | 0 | 0 | |
Income quality | -0.28 | 0.29 | 0.51 | 0.68 | |
Dividend Yield | 0.62 | 0 | 0 | 0 | |
Payout ratio | 0.49 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 0 | 0 | 0 | |
Research and developement to revenue | 1.43 | 2.91 | 0 | 0 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0.04 | 0 | 0.01 | 0.01 | |
Capex to revenue | -0.5 | 0 | 0 | 0 | |
Capex to depreciation | -1.35 | 0 | -56.67 | -4.5 | |
Stock based compensation to revenue | 1.56 | 1.9 | 0 | 0 | |
Graham number | 34.54 | 26.54 | 24.66 | 0 | |
ROIC | 1.6 | 0.12 | 0.68 | 0.31 | |
Return on tangible assets | 1.51 | -1.55 | -8.64 | -4.88 | |
Graham Net | -4.61 | -13.81 | -10.24 | 0 | |
Working capital | 94.65M | 16.18M | -15.65M | -72.74M | |
Tangible asset value | -65.87M | -203.23M | -223.82M | -270.41M | |
Net current asset value | -68.08M | -204.07M | -225.11M | -271.35M | |
Invested capital | -0.45 | -0.35 | -0.37 | -0.46 | |
Average receivables | 0 | 133.5K | 0 | 0 | |
Average payables | 0 | 1.53M | 1.61M | 4.5M | |
Average inventory | 0 | 0 | 0 | 0 | |
Days sales outstanding | 29.03 | 0 | 0 | 0 | |
Days payables outstanding | 374.13K | 0 | 0 | 0 | |
Days of inventory on hand | 0 | 0 | 0 | 0 | |
Receivables turnover | 12.57 | 0 | 0 | 0 | |
Payables turnover | 0 | 0 | 0 | 0 | |
Inventory turnover | 0 | 0 | 0 | 0 | |
ROE | -2.58 | 0.16 | 0.24 | 0.18 | |
Capex per share | -0.11 | 0 | -0.01 | 0 |
Quarterly Fundamentals Overview
Last date of statement is 2023-09-30 for Q3
Metric | History | 2020-12-31 | 2021-06-30 | 2021-12-31 | 2022-12-31 | 2023-09-30 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0 | 0 | 0 | 0 | 0 | |
Net income per share | 0 | 0 | 0 | 0 | 0 | |
Operating cash flow per share | 0 | 0 | 0 | 0 | 0 | |
Free cash flow per share | 0 | 0 | 0 | 0 | 0 | |
Cash per share | 0 | 0 | 0 | 0 | 0 | |
Book value per share | 0 | 0 | 0 | 0 | 0 | |
Tangible book value per share | 0 | 0 | 0 | 0 | 0 | |
Share holders equity per share | 0 | 0 | 0 | 0 | 0 | |
Interest debt per share | 0 | 0 | 0 | 0 | 0 | |
Market cap | 0 | 0 | 0 | 0 | 0 | |
Enterprise value | 51.99M | 68.74M | 81.76M | 121.79M | -16.13M | |
P/E ratio | 0 | 0 | 0 | 0 | 0 | |
Price to sales ratio | 0 | 0 | 0 | 0 | 0 | |
POCF ratio | 0 | 0 | 0 | 0 | 0 | |
PFCF ratio | 0 | 0 | 0 | 0 | 0 | |
P/B Ratio | 0 | 0 | 0 | 0 | 0 | |
PTB ratio | 0 | 0 | 0 | 0 | 0 | |
EV to sales | 0 | 0 | 0 | 0 | 0 | |
Enterprise value over EBITDA | 0 | 0 | 0 | -8.12 | 0 | |
EV to operating cash flow | 0 | 0 | 0 | -14.41 | 0 | |
EV to free cash flow | 0 | 0 | 0 | -14.39 | 0 | |
Earnings yield | 0 | 0 | 0 | 0 | 0 | |
Free cash flow yield | 0 | 0 | 0 | 0 | 0 | |
Debt to equity | -0.35 | -0.37 | -0.37 | -0.46 | 0 | |
Debt to assets | 3.4 | 4.22 | 13.5 | 12.2 | 0 | |
Net debt to EBITDA | 0 | 0 | 0 | -8.12 | 0 | |
Current ratio | 4.85 | 1.97 | 0.25 | 0.12 | 1.19 | |
Interest coverage | 0 | 0 | 0 | 0 | 0 | |
Income quality | 0 | 0 | 0 | 0.24 | 0 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
Capex to depreciation | 0 | 0 | 0 | -0.28 | 0 | |
Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
Graham number | 0 | 0 | 0 | 0 | 0 | |
ROIC | 0 | 0 | 0 | 0.1 | 0 | |
Return on tangible assets | 0 | 0 | 0 | -3.21 | 0 | |
Graham Net | 0 | 0 | 0 | 0 | 0 | |
Working capital | 16.18M | 8.62M | -15.65M | -72.74M | 2.73M | |
Tangible asset value | -203.23M | -207.66M | -223.82M | -270.41M | -121.74M | |
Net current asset value | -204.07M | -209M | -225.11M | -271.35M | -122.45M | |
Invested capital | -0.35 | -0.37 | -0.37 | -0.46 | 0 | |
Average receivables | 0 | 0 | 0 | 0 | 0 | |
Average payables | 0 | 0 | 0 | 0 | 0 | |
Average inventory | 0 | 0 | 0 | 0 | 0 | |
Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
Days payables outstanding | 0 | 0 | 0 | 0 | 0 | |
Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
Payables turnover | 0 | 0 | 0 | 0 | 0 | |
Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
ROE | 0 | 0 | 0 | 0.12 | 0 | |
Capex per share | 0 | 0 | 0 | 0 | 0 |
AEON Frequently Asked Questions
What is AEON Biopharma, Inc. stock symbol ?
AEON Biopharma, Inc. is a US stock , located in Newport beach of Ca and trading under the symbol AEON
What is AEON Biopharma, Inc. stock quote today ?
AEON Biopharma, Inc. stock price is $11.6 today.
Is AEON Biopharma, Inc. stock public?
Yes, AEON Biopharma, Inc. is a publicly traded company.